Valeant (VRX) PT Cut to $33 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- Wall Street ends down as US-Iran peace optimism fades
- eToro to acquire TradeZero for up to $231M to expand in US
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Valeant Pharmaceuticals Reports First Quarter 2016 Financial Results
June 7, 2016 6:00 AM EDTLAVAL, Quebec, June 7, 2016 /PRNewswire/ --
Total Revenues of $2.4 billion, an increase of 9% versus the first quarter of 2015 (restated) GAAP EPS ($1.08); Adjusted EPS (non-GAAP) $1.27 GAAP Cash Flow from Operations was $558 million, an increase of 14% versus the first quarter of 2015 (restated) Updated Full Year 2016 Guidance: Total Revenue updated to $9.9 - $10.1 billion from $11.0 - $11.2 billion Adjusted EPS (non-GAAP) updated to $6.60 - $7.00 from $8.50 - $9.50 Adjusted EBITDA (non-GAAP) is updated to $4.80 - $4.95 billion from $5.60 - $5.80 billionValeant Pharmaceuticals International,... More
